Literature DB >> 18181036

Systemic lupus erythematosus involving the nervous system: presentation, pathogenesis, and management.

Julia J Rhiannon1.   

Abstract

Neuropsychiatric syndromes in systemic lupus erythematosus (SLE) have a wide range of severity and phenotype and are fairly common. Presentations are seen involving both central and peripheral nervous systems. Pathogenic mechanisms are thought to include vascular occlusion and hemorrhage, antineuronal antibodies, cytokine effects, choroid plexus dysfunction, neuroendocrine-immune effects, and direct central nervous system (CNS) tissue injury. Work-up includes serum, cerebrospinal fluid (CSF), and imaging studies. Treatment is based on severity and phenotype and includes steroids, anticoagulants, antidepressants, and cytotoxic approaches. Much remains to be done in terms of further elucidation of pathologic processes, correlation of these mechanisms with specific phenotypes, and management of the most severe presentations of neuropsychiatric lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18181036     DOI: 10.1007/s12016-007-8052-z

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  37 in total

1.  Cognitive impairment in systemic lupus erythematosus: a follow-up study.

Authors:  S Carlomagno; S Migliaresi; L Ambrosone; M Sannino; G Sanges; G Di Iorio
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

Review 2.  Psychological aspects of systemic lupus erythematosus: cognitive function, mood, and self-report.

Authors:  S D Denburg; R M Carbotte; J A Denburg
Journal:  J Rheumatol       Date:  1997-05       Impact factor: 4.666

Review 3.  To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system.

Authors:  Yehuda Shoenfeld
Journal:  J Autoimmun       Date:  2007-03-26       Impact factor: 7.094

Review 4.  Antiphospholipid antibodies: lessons from the bench.

Authors:  Takao Koike; Miyuki Bohgaki; Olga Amengual; Tatsuya Atsumi
Journal:  J Autoimmun       Date:  2007-03-23       Impact factor: 7.094

Review 5.  The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation.

Authors:  F G I Jennekens; L Kater
Journal:  Rheumatology (Oxford)       Date:  2002-06       Impact factor: 7.580

6.  Factors associated with anxiety, depression and suicide ideation in female outpatients with SLE in Japan.

Authors:  R Ishikura; N Morimoto; K Tanaka; N Kinukawa; S Yoshizawa; T Horiuchi; H Nakashima; T Otsuka
Journal:  Clin Rheumatol       Date:  2001       Impact factor: 2.980

Review 7.  B cell targeted therapy in autoimmunity.

Authors:  Miri Blank; Yehuda Shoenfeld
Journal:  J Autoimmun       Date:  2007-03-27       Impact factor: 7.094

8.  Magnetic resonance imaging of the brain in systemic lupus erythematosus.

Authors:  M R Gonzalez-Crespo; F J Blanco; A Ramos; E Ciruelo; I Mateo; M A Lopez Pino; J J Gomez-Reino
Journal:  Br J Rheumatol       Date:  1995-11

Review 9.  Psychiatric manifestations in systemic lupus erythematosus.

Authors:  Ljudmila Stojanovich; Gisele Zandman-Goddard; Sanja Pavlovich; Natasa Sikanich
Journal:  Autoimmun Rev       Date:  2007-03-12       Impact factor: 9.754

Review 10.  Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?

Authors:  Ilaria Cavazzana; Nebuloni Manuela; Cetin Irene; Acaia Barbara; Saino Sara; Borghi Maria Orietta; Tincani Angela; Tedesco Francesco; Meroni Pier Luigi
Journal:  J Autoimmun       Date:  2007-04-06       Impact factor: 7.094

View more
  19 in total

1.  Vasculitis: current status and future directions.

Authors:  Pierre Youinou
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

2.  Cutting edge issues in autoimmunity.

Authors:  Yaniv Sherer; Torsten Matthias; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

3.  Blood pressure and vascular dysfunction underlie elevated cerebral blood flow in systemic lupus erythematosus.

Authors:  Charles Gasparovic; Clifford Qualls; Ernest R Greene; Wilmer L Sibbitt; Carlos A Roldan
Journal:  J Rheumatol       Date:  2012-01-15       Impact factor: 4.666

4.  Middle cerebral artery resistivity and pulsatility indices in systemic lupus erythematosus: evidence for hyperperfusion.

Authors:  E R Greene; K A Yonan; J M Sharrar; W L Sibbitt; C A Roldan
Journal:  Lupus       Date:  2011-11-29       Impact factor: 2.911

5.  Extreme hypoglycorrhachia: not always bacterial meningitis.

Authors:  George M Viola
Journal:  Nat Rev Neurol       Date:  2010-09-14       Impact factor: 42.937

6.  Elevated cerebral blood flow and volume in systemic lupus measured by dynamic susceptibility contrast magnetic resonance imaging.

Authors:  Charles M Gasparovic; Carlos A Roldan; Wilmer L Sibbitt; Clifford R Qualls; Paul G Mullins; Janeen M Sharrar; J Jeremy Yamamoto; H Jeremy Bockholt
Journal:  J Rheumatol       Date:  2010-06-15       Impact factor: 4.666

7.  Evaluation of oxygen extraction fraction in systemic lupus erythematosus patients using quantitative susceptibility mapping.

Authors:  Mari Miyata; Shingo Kakeda; Kohsuke Kudo; Shigeru Iwata; Yoshiya Tanaka; Yi Wang; Yukunori Korogi
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-16       Impact factor: 6.200

Review 8.  Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus.

Authors:  Samir D Bhangle; Neil Kramer; Elliot D Rosenstein
Journal:  Rheumatol Int       Date:  2013-04-16       Impact factor: 2.631

Review 9.  Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers.

Authors:  Hélène Jeltsch-David; Sylviane Muller
Journal:  Nat Rev Neurol       Date:  2014-09-09       Impact factor: 42.937

10.  Complete factor I deficiency due to dysfunctional factor I with recurrent aseptic meningo-encephalitis.

Authors:  Filomeen Haerynck; Patrick Stordeur; Johan Vandewalle; Rudy Van Coster; Victoria Bordon; Frans De Baets; Petra Schelstraete; Cédric Javaux; Marie-Rose Bouvry; Véronique Fremeaux-Bacchi; Joke Dehoorne
Journal:  J Clin Immunol       Date:  2013-10-20       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.